US Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Breyanzi (Lisocabtagene Maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Bristol Myers Squibb announced that the FDA has accepted the supplemental Biologics License Application for Breyanzito expand its current indication to include the treatment of adult patients with relapsed or refractory CLL or SLL who received a prior Bruton tyrosine kinase inhibitor and B cell lymphoma 2 inhibitor.